Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced Wound Care – Untapped Opportunities

Executive Summary

With worldwide revenues projected to reach $6 billion in 2015, mega-deals and innovative game-changing technologies have transformed the advanced wound care market into a robust, high-tech arena in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.

You may also be interested in...



Acquisitions, New Technologies Reshaping Advanced Wound Care

Acquisitions and innovation are rapidly changing the dynamics in the global advanced wound care market, a high need, high growth market estimated at $5.4 billion in 2013. With the number of chronic wounds in major countries estimated at a whopping 26.7 million, the global advanced wound care market is projected to grow at a brisk 6% CAGR, reaching $7.3 billion by 2018.

Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials

The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.

Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes

Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel